UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2205-8
Program Prior Authorization/Medical Necessity
Medication *Skyrizi® (risankizumab-rzaa) injection
*This program applies to the subcutaneous formulations of Skyrizi
P&T Approval Date 5/2020, 5/2021, 6/2021, 3/2022, 8/2022, 7/2023, 5/2024, 7/2024
Effective Date 10/1/2024
1. Background:
Skyrizi is an interleukin-23 antagonist indicated for the treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic therapy or phototherapy, active psoriatic
arthritis in adults, moderately to severely active Crohn's disease in adults, and moderately to
severely active ulcerative colitis in adults.
2. Coverage Criteriaa:
A. Plaque Psoriasis
1. Initial Authorization
a. Skyrizi will be approved based on all of the following criteria:
(1) Diagnosis of moderate to severe plaque psoriasis
-AND-
(2) One of the following:
(a) All of the following:
i. Greater than or equal to 3% body surface area involvement,
palmoplantar, facial, genital involvement, or severe scalp psoriasis
-AND-
ii. History of failure to one of the following topical therapies, unless
contraindicated or clinically significant adverse effects are experienced
(document drug, date, and duration of trial):
a. Corticosteroids (e.g., betamethasone, clobetasol, desonide)
b. Vitamin D analogs (e.g., calcitriol, calcipotriene)
c. Tazarotene
d. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
e. Anthralin
f. Coal tar
-AND-
© 2024 UnitedHealthcare Services, Inc.
1
iii. History of failure to a 3 month trial of methotrexate at maximally
indicated dose, unless contraindicated or clinically significant adverse
effects are experienced (document date and duration of trial)b
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of plaque psoriasis as documented by claims
history or submission of medical records (Document drug, date, and
duration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Stelara
(ustekinumab), Tremfya (guselkumab)].
-OR-
(c) Both of the following:
i. Patient is currently on Skyrizi therapy as documented by claims history or
submission of medical records (Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in
the prescriber’s office, or any form of assistance from the Abbvie
sponsored Skyrizi Complete program (e.g., sample card which can be
redeemed at a pharmacy for a free supply of medication) as a means
to establish as a current user of Skyrizi*
-AND-
(3) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Stelara
(ustekinumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
-AND-
(4) Prescribed by or in consultation with a dermatologist
* Patients requesting initial authorization who were established on therapy via the
receipt of a manufacturer supplied sample at no cost in the prescriber’s office or any
form of assistance from the Abbvie sponsored Skyrizi Complete program shall be
required to meet initial authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
2
2. Reauthorization
a. Skyrizi will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Skyrizi therapy
-AND-
(2) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),
Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq
(brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
B. Psoriatic Arthritis (PsA)
1. Initial Authorization
a. Skyrizi will be approved based on all of the following criteria:
(1) Diagnosis of active psoriatic arthritis
-AND-
(3) One of the following:
(a) History of failure to a 3 month trial of methotrexate at the maximally
indicated dose, unless contraindicated or clinically significant adverse effects
are experienced (document date and duration of trial)b
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of psoriatic arthritis as documented by claims
history or submission of medical records (Document drug, date, and
duration of therapy) [e.g., adalimumab, Cimzia (certolizumab), Rinvoq
(upadacitinib), Simponi (golimumab), Stelara (ustekinumab), Tremfya
(guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast),
Rinvoq (upadacitinib)]
-OR-
(c) Both of the following:
i. Patient is currently on Skyrizi therapy as documented by claims history
or submission of medical records (Document date and duration of
therapy):
© 2024 UnitedHealthcare Services, Inc.
3
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from the Abbvie sponsored
Skyrizi Complete program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Skyrizi*
-AND-
(3) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab), Tremfya
(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
-AND-
(4) Prescribed by or in consultation with one of the following:
(a) Rheumatologist
(b) Dermatologist
* Patients requesting initial authorization who were established on therapy via the
receipt of a manufacturer supplied sample at no cost in the prescriber’s office or any
form of assistance from the Abbvie sponsored Skyrizi Complete program shall be
required to meet initial authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Skyrizi will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Skyrizi therapy
-AND-
(2) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Stelara
(ustekinumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
4
C. Crohn’s Disease (CD)
1. Initial Authorization for Maintenance Dosing
a. Skyrizi will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active Crohn’s disease
-AND-
(2) One of the following:
(a) Patient has been established on therapy with Skyrizi under an active
UnitedHealthcare prior authorization for the treatment of moderately to
severely active Crohn’s disease
-OR-
(b) Both of the following:
i. Patient is currently on Skyrizi therapy for moderately to severely active
Crohn’s disease as documented by claims history or submission of
medical records (Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from the Abbvie sponsored
Skyrizi Complete program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Skyrizi*
-AND-
(3) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Stelara
(ustekinumab)]
-AND-
(4) Prescribed by or in consultation with a gastroenterologist
* Patients requesting initial authorization who were established on therapy via the
receipt of a manufacturer supplied sample at no cost in the prescriber’s office or any
form of assistance from the Abbvie sponsored Skyrizi Complete program shall be
required to meet initial authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
5
2. Reauthorization
a. Skyrizi will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Skyrizi therapy
-AND-
(2) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Stelara
(ustekinumab)]
Authorization will be issued for 12 months.
D. Ulcerative Colitis (UC)
1. Initial Authorization for Maintenance Dosing
a. Skyrizi will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active ulcerative colitis
-AND-
(2) One of the following:
(a) Patient has been established on therapy with Skyrizi under an active
UnitedHealthcare medical benefit prior authorization for the treatment
of moderately to severely active ulcerative colitis
-OR-
(b) Both of the following:
i. Patient is currently on Skyrizi therapy for moderately to severely active
ulcerative colitis as documented by claims history or submission of
medical records (Document date and duration of therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from the Abbvie sponsored
Skyrizi Complete program (e.g., sample card which can be redeemed at a
pharmacy for a free supply of medication) as a means to establish as a
current user of Skyrizi*
-AND-
© 2024 UnitedHealthcare Services, Inc.
6
(3) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab), adalimumab]
-AND-
(4) Prescribed by or in consultation with a gastroenterologist
* Patients requesting initial authorization who were established on therapy via the
receipt of a manufacturer supplied sample at no cost in the prescriber’s office or any
form of assistance from the Abbvie sponsored Skyrizi Complete program shall be
required to meet initial authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Skyrizi will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Skyrizi therapy
-AND-
(2) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab), adalimumab]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b For Connecticut, Kentucky, and Mississippi business only a 30-day trial will be required.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Skyrizi [package insert]. North Chicago, IL: AbbVie Inc.; June 2024.
2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of
psoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.
© 2024 UnitedHealthcare Services, Inc.
7
3. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with an
emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.
4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis
with topical therapies. J Am Acad Dermatol 2009;60(4):643-59.
5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and
photochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.
6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with
traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.
7. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris – update
2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm Venereol
2015;29:2277-94.
8. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for
the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment
of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J
Am Acad Dermatol. 2011 Jul;65(1):137-74.
9. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management
and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.
10. Lichtenstein GR, Loftus EV, Isaacs KL, et al ACG clinical guideline: management of Crohn’s
disease in adults. Am J Gastroenterol. 2018; 113:481-517.
Program Prior Authorization/Medical Necessity – Skyrizi® (risankizumab-rzaa)
Change Control
5/2020 New program
5/2021 Annual review. Removed preceding month requirement from failure
criteria. Removed prescriber requirement from reauthorization criteria.
Removed drug documentation where only one drug is required.
Reference updated.
6/2021 Added coverage criteria for patients previously treated with a biologic
DMARD. Added clarification that submission of medical records is
required documenting previous or current therapy with a biologic
DMARD in order to bypass step through non-biologic therapies if claim
history not available.
3/2022 Clinical coverage criteria updated to add active psoriatic arthritis.
Updated reference.
8/2022 Clinical coverage criteria and background updated to add Crohn’s
disease. Added state mandate footnote to include Mississippi. Added
Rinvoq as Janus kinase inhibitor example. Updated reference.
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
5/2024 Annual review with no changes to coverage criteria. Updated state
mandate footnote and references.
7/2024 Updated clinical coverage criteria and background to add ulcerative
colitis. Updated active prior authorization verbiage under Crohn’s
disease with no change to clinical intent. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
8